Table 3. Studies describing the role of HIPEC in primary ovarian cancer.

HIPEC: hyperthermic intraperitoneal chemotherapy

Study	Design	Inclusion criteria	Drugs	Results
Lim 2017 [20]	Randomized controlled trial: HIPEC+ cytoreductive surgery (CRS) + systemic chemotherapy (n = 92), CRS + systemic chemotherapy (n = 92)	Primary ovarian cancer stages 3 and 4	Cisplatin 75 mg/m2, 90 min at 41.5⁰C	5-year progression-free survival (p = 0.569): HIPEC: 20.9%, Control: 16%; 5-year overall survival (p = 0.574): HIPEC: 51%, Control: 49.4%
Van Driel 2018 [21]	Multicentric randomized controlled trial: CRS + HIPEC (n = 122), CRS alone (n= 123)	Stage III ovarian cancer patients who have received neoadjuvant chemotherapy with carboplatin and paclitaxel with stable disease after 3 cycles	Cisplatin 100 mg/m2, 90 min at 40⁰C	Progression[Ns1]-free survival: HIPEC: 14.2 months, Control: 10.7 months; Median overall survival: HIPEC: 45.7 months, Control: 33.9 months Adverse events of grade 3 and 4: 25% and 27%
Ansaloni et al. 2012 [22]	Open prospective phase 2 study	Primary or recurrent peritoneal carcinomatosis with ovarian cancer; Primary (n=9), Recurrent (n=30)	Cisplatin 100 mg/m2, Paclitaxel 175 mg/m2, Doxorubicin 35 mg/m2, 90 min at 41.5⁰C, 66% received cisplatin + doxorubicin.	Recurrence rate 59%; Mean recurrence time 14.4 months; Mean hospital stay 23.8 days